Cargando…
Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
BACKGROUND: Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide. METHODS: We conducted a retrospective cohort study by utilizing multi-insti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547475/ https://www.ncbi.nlm.nih.gov/pubmed/33036617 http://dx.doi.org/10.1186/s12933-020-01148-8 |
_version_ | 1783592428590071808 |
---|---|
author | Chang, Kai-Cheng Shao, Shih-Chieh Kuo, Shihchen Yang, Chen-Yi Chen, Hui-Yu Chan, Yuk-Ying Ou, Huang-Tz |
author_facet | Chang, Kai-Cheng Shao, Shih-Chieh Kuo, Shihchen Yang, Chen-Yi Chen, Hui-Yu Chan, Yuk-Ying Ou, Huang-Tz |
author_sort | Chang, Kai-Cheng |
collection | PubMed |
description | BACKGROUND: Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide. METHODS: We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016–2018 in Taiwan and followed up until 2019. Effectiveness outcomes were assessed at every 3 months in the 1-year follow-up. Propensity score techniques were applied to enhance between-group comparability. Significant differences in changes of effectiveness outcomes between treatment groups during the follow-up were examined and further analyzed using mixed-model repeated-measures approaches. RESULTS: A total of 1512 subjects receiving dulaglutide and 1513 subjects receiving liraglutide were identified. At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: − 1.06%, p < 0.001; liraglutide: − 0.83%, p < 0.001), with a significant between-group difference (− 0.23%, 95% confidence interval − 0.38 to − 0.08%, p < 0.01). Both treatments yielded significant declines in weight, alanine aminotransferase level, and estimated glomerular filtration rate from baseline (dulaglutide: − 1.14 kg, − 3.08 U/L and − 2.08 mL/min/1.73 m(2), p < 0.01; liraglutide: − 1.64 kg, − 3.65 U/L and − 2.33 mL/min/1.73 m(2), p < 0.001), whereas only dulaglutide yielded a significant systolic blood pressure reduction (− 2.47 mmHg, p < 0.001). Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant. CONCLUSIONS: In real-world T2D patients, dulaglutide versus liraglutide was associated with better glycemic control and comparable effects on changes of weight, blood pressure, and liver and renal functions. |
format | Online Article Text |
id | pubmed-7547475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75474752020-10-13 Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis Chang, Kai-Cheng Shao, Shih-Chieh Kuo, Shihchen Yang, Chen-Yi Chen, Hui-Yu Chan, Yuk-Ying Ou, Huang-Tz Cardiovasc Diabetol Original Investigation BACKGROUND: Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide. METHODS: We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016–2018 in Taiwan and followed up until 2019. Effectiveness outcomes were assessed at every 3 months in the 1-year follow-up. Propensity score techniques were applied to enhance between-group comparability. Significant differences in changes of effectiveness outcomes between treatment groups during the follow-up were examined and further analyzed using mixed-model repeated-measures approaches. RESULTS: A total of 1512 subjects receiving dulaglutide and 1513 subjects receiving liraglutide were identified. At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: − 1.06%, p < 0.001; liraglutide: − 0.83%, p < 0.001), with a significant between-group difference (− 0.23%, 95% confidence interval − 0.38 to − 0.08%, p < 0.01). Both treatments yielded significant declines in weight, alanine aminotransferase level, and estimated glomerular filtration rate from baseline (dulaglutide: − 1.14 kg, − 3.08 U/L and − 2.08 mL/min/1.73 m(2), p < 0.01; liraglutide: − 1.64 kg, − 3.65 U/L and − 2.33 mL/min/1.73 m(2), p < 0.001), whereas only dulaglutide yielded a significant systolic blood pressure reduction (− 2.47 mmHg, p < 0.001). Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant. CONCLUSIONS: In real-world T2D patients, dulaglutide versus liraglutide was associated with better glycemic control and comparable effects on changes of weight, blood pressure, and liver and renal functions. BioMed Central 2020-10-09 /pmc/articles/PMC7547475/ /pubmed/33036617 http://dx.doi.org/10.1186/s12933-020-01148-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Investigation Chang, Kai-Cheng Shao, Shih-Chieh Kuo, Shihchen Yang, Chen-Yi Chen, Hui-Yu Chan, Yuk-Ying Ou, Huang-Tz Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis |
title | Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis |
title_full | Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis |
title_fullStr | Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis |
title_full_unstemmed | Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis |
title_short | Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis |
title_sort | comparative effectiveness of dulaglutide versus liraglutide in asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547475/ https://www.ncbi.nlm.nih.gov/pubmed/33036617 http://dx.doi.org/10.1186/s12933-020-01148-8 |
work_keys_str_mv | AT changkaicheng comparativeeffectivenessofdulaglutideversusliraglutideinasiantype2diabetespatientsamultiinstitutionalcohortstudyandmetaanalysis AT shaoshihchieh comparativeeffectivenessofdulaglutideversusliraglutideinasiantype2diabetespatientsamultiinstitutionalcohortstudyandmetaanalysis AT kuoshihchen comparativeeffectivenessofdulaglutideversusliraglutideinasiantype2diabetespatientsamultiinstitutionalcohortstudyandmetaanalysis AT yangchenyi comparativeeffectivenessofdulaglutideversusliraglutideinasiantype2diabetespatientsamultiinstitutionalcohortstudyandmetaanalysis AT chenhuiyu comparativeeffectivenessofdulaglutideversusliraglutideinasiantype2diabetespatientsamultiinstitutionalcohortstudyandmetaanalysis AT chanyukying comparativeeffectivenessofdulaglutideversusliraglutideinasiantype2diabetespatientsamultiinstitutionalcohortstudyandmetaanalysis AT ouhuangtz comparativeeffectivenessofdulaglutideversusliraglutideinasiantype2diabetespatientsamultiinstitutionalcohortstudyandmetaanalysis |